The R21/Matrix-M malaria vaccine generates nearly identical antibodies as those following a natural infection, helping explain why the vaccine confers such strong protection against the earliest life stage of malaria parasites, according to research published in the Journal of Experimental Medicine.
This article was originally published on MedicalXpress.com